Biocon Biologics

Rediff.com » News » Biocon Biologics

News for Biocon Biologics

News
Business

Biocon drug gets nod for use in moderate to severe COVID-19 patients

Biotechnology major Biocon on Saturday announced that its 'breakthrough drug', Itolizumab has received Drugs Controller General of India's (DCGI) approval for its use in moderate to......

'No preparedness planning, no accountability, no action plan'

'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......

Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial. The company......

Postgraduate diploma course in bioinformatics

Postgraduate diploma course in bioinformaticsThe Institute of Bioinformatics and Applied Biotechnology,Bangalore, announcesadmissions for its third batch,2004-2005.The IBAB has been set up by......

Rupee Slide: Tough Times For Overseas Corporate Debt

Raising overseas debt has become prohibitively expensive due to the depreciating rupee. Photograph: Kind courtesy Jatinder Jeetu/Pixabay Indian companies' foreign borrowings plunged 20.2 per cent......

Biocon Biologics Plan Molecule Launch Every 1-2 Years

'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.' Photograph: PTI Photo The market share that Biocon......

'Real growth and opportunity are going to come from GLP-1'

'It is not just the US and European opportunity, but it is a huge global opportunity.' Photograph: Kind courtesy Biocon The peptides and GLP-1 class of drugs that are offering breakthrough......

Jt drugs controller waives trial of Biocon drug; arrested

The CBI has arrested Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive the phase three clinical trial of the Insulin Aspart injection, a product of Biocon......

'Aim to be among top three biosimilar players in world'

'We've got a huge track record and success in bringing several biosimilars to the market.' IMAGE: Biocon Biologics, Biocon Park, Bengaluru. Photograph: Kind courtesy Biocon Biologics/Facebook......

Rediff News

Biocon Biologics

News for Biocon Biologics

Biocon drug gets nod for use in moderate to severe COVID-19 patients

'No preparedness planning, no accountability, no action plan'

Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Postgraduate diploma course in bioinformatics

Rupee Slide: Tough Times For Overseas Corporate Debt

Biocon Biologics Plan Molecule Launch Every 1-2 Years

'Real growth and opportunity are going to come from GLP-1'

Jt drugs controller waives trial of Biocon drug; arrested

'Aim to be among top three biosimilar players in world'

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS